Evotec has announced the extension of the drug discovery alliance for three years with Genentech, a Roche Group member.
Subscribe to our email newsletter
The extension of the collaboration that was initiated in May 2010 further validates Evotec’s technology platform, according to the company.
Evotec chief operating officer Dr Mario Polywka said, "We are delighted and proud that Genentech has decided to extend the current agreement. Both sets of scientists have collaborated very closely over the past few years and this extension is validation of the value we bring to Genentech’s discovery programmes."
Evotec is a drug discovery alliance and development partnership company focused on advancing new product approaches with pharmaceutical and biotechnology companies.